Clinical

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

A cross-sectional analysis found diverging skin cancer trends by region, with basal cell carcinoma projected to have the highest global burden by 2050.

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.

Older adults with prior adenomas had slightly higher CRC risk, but 10-year CRC incidence was far outweighed by non-CRC mortality, supporting reduced surveillance colonoscopy use.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

The disease progression of patients with MS had an association with their serum protein level.

Skin cancers arising from burn scars carry high recurrence and mortality risks, with squamous cell carcinoma considered most common.

Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.

An analysis of the POSITIVE study showed that tildrakizumab not only clears skin but substantially reduces itch, pain, and fatigue, with psychological well-being scores ultimately surpassing general population norms by year 2.

In psoriatic arthritis, high BMI and smoking raise disease activity, while weight-focused lifestyle changes improve treat-to-target odds at one year.

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

Circulating tumor DNA (ctDNA) detection is linked to worse survival outcomes in resectable melanoma, but high false-negative rates limit its use in surveillance or de-escalation.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

Younger patients with early-onset CRC, especially men and racial and ethnic minority groups in urban areas, face a higher risk of cardiovascular death.

Eighteen Legionella cases were linked to Kaiser Santa Clara as officials investigate the source and infection risks.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to equitable access.

Across a landmark guideline update, a primary prevention trial, and the first treat-to-target proof of concept, the message is consistent: lower LDL for longer saves lives—and achieving that goal in practice demands goals, teams, tools, and lifestyle as the foundation.